Integra LifeSciences (NASDAQ:IART) Updates FY24 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its FY24 earnings guidance on Monday morning. The company provided earnings per share guidance of $3.01-3.11 for the period, compared to the consensus earnings per share estimate of $3.19. The company issued revenue guidance of $1.67-1.69 billion, compared to the consensus revenue estimate of $1.62 billion. Integra LifeSciences also updated its FY 2024 guidance to 3.010-3.110 EPS.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART traded up $0.28 during trading on Thursday, reaching $25.19. The stock had a trading volume of 397,500 shares, compared to its average volume of 818,352. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45. The business has a fifty day moving average price of $32.67 and a 200-day moving average price of $38.15. The stock has a market cap of $1.98 billion, a PE ratio of 30.01, a PEG ratio of 0.87 and a beta of 1.17. Integra LifeSciences has a 1-year low of $22.36 and a 1-year high of $50.78.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, hitting analysts’ consensus estimates of $0.55. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The firm had revenue of $368.90 million for the quarter, compared to the consensus estimate of $361.96 million. During the same quarter last year, the business posted $0.74 earnings per share. The firm’s revenue was down 3.2% compared to the same quarter last year. On average, equities analysts forecast that Integra LifeSciences will post 3.19 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on IART shares. Citigroup upgraded Integra LifeSciences from a sell rating to a neutral rating and set a $38.00 target price on the stock in a research report on Wednesday, April 3rd. Bank of America lowered their target price on Integra LifeSciences from $42.00 to $26.00 and set an underperform rating for the company in a research note on Tuesday. StockNews.com cut Integra LifeSciences from a buy rating to a hold rating in a research note on Tuesday, April 30th. JMP Securities lowered their price objective on Integra LifeSciences from $49.00 to $40.00 and set a market outperform rating for the company in a research report on Tuesday. Finally, Oppenheimer cut Integra LifeSciences from an outperform rating to a market perform rating in a research report on Tuesday. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Integra LifeSciences has a consensus rating of Hold and an average price target of $36.80.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.